Tissue factor‐dependent procoagulant activity of isolated human hepatocytes: Relevance to liver cell transplantation

Xavier Stéphenne, Olivier Vosters, Mustapha Najimi, Claire Beuneu, Dung Khuu Ngoc, Walter Wijns, Michel Goldman, Etienne M. Sokal – 29 March 2007 – Liver cell transplantation (LCT) aims to correct inborn liver function defects by infusing metabolically active cells into the diseased liver. Further improvement in LCT might depend on the prevention of early loss of transplanted cells.

Early posttransplantation portal vein stenosis following living donor liver transplantation: Percutaneous transhepatic primary stent placement

Gi‐Young Ko, Kyu‐Bo Sung, Hyun‐Ki Yoon, SungGyu Lee – 29 March 2007 – Surgical treatments have usually been preferred for early posttransplantation portal inflow abnormalities. However, these treatments are limited due to their technical difficulty and multiple complicating factors. The present study reports the efficacy and safety of percutaneous transhepatic primary stent placement to treat early posttransplantation (≤1 month) portal vein (PV) stenosis. A total of 9 patients who had undergone living donor liver transplantation underwent percutaneous stent placement to treat PV stenosis.

Risk factors for invasive aspergillosis in living donor liver transplant recipients

Makoto Osawa, Yutaka Ito, Toyohiro Hirai, Rie Isozumi, Shunji Takakura, Yasuhiro Fujimoto, Yoshitsugu Iinuma, Satoshi Ichiyama, Koichi Tanaka, Michiaki Mishima – 29 March 2007 – Invasive aspergillosis (IA) is a severe complication of liver transplantation. Risk factors for IA after deceased donor liver transplantation (DDLT) have been presented in several reports, but are not well established for living donor liver transplant recipients. Here, a retrospective case‐control study was performed.

B‐cell surface marker analysis for improvement of rituximab prophylaxis in ABO‐incompatible adult living donor liver transplantation

Hiroto Egawa, Katsuyuki Ohmori, Hironori Haga, Hiroaki Tsuji, Kimiko Yurugi, Aya Miyagawa‐Hayashino, Fumitaka Oike, Akinari Fukuda, Jun Yoshizawa, Yasutsugu Takada, Koichi Tanaka, Taira Maekawa, Kazue Ozawa, Shinji Uemoto – 29 March 2007 – Although the effectiveness of rituximab has been reported in ABO blood group (ABO)‐incompatible (ABO‐I) organ transplantation, the protocol is not yet established.

Functional and morphological comparison of three primary liver cell types cultured in the AMC bioartificial liver

Paul P.C. Poyck, Ruurdtje Hoekstra, Albert C.W.A. van Wijk, Chiara Attanasio, Fulvio Calise, Robert A.F.M. Chamuleau, Thomas M. van Gulik – 29 March 2007 – The selection of a cell type for bioartificial liver (BAL) systems for the treatment of patients with acute liver failure is in part determined by issues concerning patient safety and cell availability. Consequently, mature porcine hepatocytes (MPHs) have been widely applied in BAL systems. The success of clinical BAL application systems is, however, largely dependent on the functionality and stability of hepatocytes.

Subscribe to